Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q5W0Q7
UPID:
USPL1_HUMAN
Alternative names:
Ubiquitin-specific peptidase-like protein 1
Alternative UPACC:
Q5W0Q7; Q14109; Q6AI45; Q8IY30; Q8IYE8
Background:
SUMO-specific isopeptidase USPL1, also known as Ubiquitin-specific peptidase-like protein 1, plays a pivotal role in protein desumoylation. It exhibits a high affinity for SUMO proteins, particularly SUMO2 and SUMO3, facilitating efficient cleavage. USPL1 is instrumental in RNA polymerase-II-mediated snRNA transcription within Cajal bodies and is a key component of complexes binding to U snRNA genes.
Therapeutic significance:
Understanding the role of SUMO-specific isopeptidase USPL1 could open doors to potential therapeutic strategies.